What is SS-31?
SS-31 is a synthetic tetrapeptide that selectively targets the inner mitochondrial membrane, where cells generate most of their usable energy. Its technical name is elamipretide, and it was developed by Dr. Hazel Szeto at Weill Cornell Medical College and Dr. Peter Schiller at the Montreal Clinical Research Institute. The name SS-31 stands for Szeto-Schiller peptide 31.
Unlike compounds that broadly influence metabolic signaling, SS-31 binds cardiolipin, a phospholipid that helps organize the inner membrane and support the electron transport chain. By stabilizing cardiolipin under cellular stress, SS-31 is being studied for its ability to reduce excess reactive oxygen species, limit electron leakage, and improve the efficiency of existing mitochondria.
That repair-first mechanism separates SS-31 from compounds intended primarily to increase metabolic signaling or supply cellular fuel. Research has explored elamipretide across mitochondrial disease, skeletal muscle function, cardiovascular performance, kidney disease, aging, and recovery, with the strongest regulatory validation coming from its approved use in Barth syndrome.
Benefits
Mitochondrial Repair
SS-31 is about mitochondrial quality, not quantity. Research in aged animals showed improved morphology,
restored cristae structure, and reduced markers of cellular senescence.
Improved Energy Production
By stabilizing the electron transport chain and reducing electron leakage, SS-31 can improve ATP output from existing mitochondria.
Reduced Oxidative Stress
SS-31 reduces mitochondrial reactive oxygen species production at the source by protecting cardiolipin and membrane function.
Organ Protection
Heart, kidney, brain, and skeletal muscle are highly dependent on mitochondrial function and are common targets in SS-31 research.
Functional Aging Support
Preclinical aging research suggests potential improvements in frailty, cardiac strain, skeletal muscle fatigue resistance, and inflammatory signaling.
Exercise Capacity
In Barth syndrome research, elamipretide was associated with meaningful improvements in functional measures such as walking capacity.
SS-31 vs NAD+ vs MOTS-c
These compounds are often grouped together because they relate to mitochondrial health, but they play different roles.
SS-31
The mechanic. Targets cardiolipin to support mitochondrial structure and inner-membrane efficiency.
NAD+
The fuel. Supports redox reactions and cellular energy pathways that functioning mitochondrial machinery depends on.
MOTS-c
The metabolic signal. Studied for pathways associated with AMPK activation, metabolic flexibility, and cellular stress response.
Who Benefits Most?
Community interest is strongest among adults dealing with declining energy, slower recovery, metabolic strain, or other signs of accumulated mitochondrial stress. Younger, metabolically healthy users may notice less.
Age-Related Decline
A repair-focused approach becomes more relevant as mitochondrial efficiency and resilience decline with age.
Slow Recovery
Users often pursue SS-31 when training recovery, exercise tolerance, and baseline energy begin to slip.
Metabolic Strain
SS-31 may be relevant when mitochondrial stress is part of a broader metabolic or energy-production problem.
Poor Response to NAD+ or MOTS-c
Some community users explore SS-31 when NAD+ or MOTS-c produces little noticeable benefit, although this sequence has not been validated clinically.
